Switch to:
Also traded in: Israel

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 39.17
KMDA's Cash to Debt is ranked lower than
52% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 58.56 vs. KMDA: 39.17 )
Ranked among companies with meaningful Cash to Debt only.
KMDA' s Cash to Debt Range Over the Past 10 Years
Min: 1.32  Med: 5.54 Max: N/A
Current: 39.17
Equity to Asset 0.67
KMDA's Equity to Asset is ranked lower than
52% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. KMDA: 0.67 )
Ranked among companies with meaningful Equity to Asset only.
KMDA' s Equity to Asset Range Over the Past 10 Years
Min: 0.28  Med: 0.64 Max: 0.71
Current: 0.67
0.28
0.71
F-Score: 4
Z-Score: 2.16
M-Score: -2.43
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -10.10
KMDA's Operating margin (%) is ranked higher than
66% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -77.71 vs. KMDA: -10.10 )
Ranked among companies with meaningful Operating margin (%) only.
KMDA' s Operating margin (%) Range Over the Past 10 Years
Min: -121.42  Med: -16.15 Max: 5.83
Current: -10.1
-121.42
5.83
Net-margin (%) -10.92
KMDA's Net-margin (%) is ranked higher than
66% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -78.92 vs. KMDA: -10.92 )
Ranked among companies with meaningful Net-margin (%) only.
KMDA' s Net-margin (%) Range Over the Past 10 Years
Min: -170.4  Med: -18.59 Max: 0.63
Current: -10.92
-170.4
0.63
ROE (%) -11.32
KMDA's ROE (%) is ranked higher than
67% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -32.89 vs. KMDA: -11.32 )
Ranked among companies with meaningful ROE (%) only.
KMDA' s ROE (%) Range Over the Past 10 Years
Min: -196.96  Med: -20.08 Max: 1.83
Current: -11.32
-196.96
1.83
ROA (%) -7.68
KMDA's ROA (%) is ranked higher than
69% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -28.03 vs. KMDA: -7.68 )
Ranked among companies with meaningful ROA (%) only.
KMDA' s ROA (%) Range Over the Past 10 Years
Min: -59.2  Med: -11.02 Max: 0.58
Current: -7.68
-59.2
0.58
ROC (Joel Greenblatt) (%) -16.50
KMDA's ROC (Joel Greenblatt) (%) is ranked higher than
72% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. KMDA: -16.50 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
KMDA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -111.83  Med: -13.79 Max: 26.43
Current: -16.5
-111.83
26.43
Revenue Growth (3Y)(%) -2.70
KMDA's Revenue Growth (3Y)(%) is ranked lower than
66% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. KMDA: -2.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
KMDA' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -2.7  Med: 25.35 Max: 44.1
Current: -2.7
-2.7
44.1
EPS Growth (3Y)(%) 35.10
KMDA's EPS Growth (3Y)(%) is ranked lower than
99.99% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. KMDA: 35.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
KMDA' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -100  Med: -58.90 Max: 35.1
Current: 35.1
-100
35.1
» KMDA's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-30)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

KMDA Guru Trades in Q2 2015

Jim Simons 204,400 sh (+20.88%)
John Paulson 739,356 sh (unchged)
» More
Q3 2015

KMDA Guru Trades in Q3 2015

John Paulson 739,356 sh (unchged)
Jim Simons 156,500 sh (-23.43%)
» More
Q4 2015

KMDA Guru Trades in Q4 2015

Jim Simons 166,300 sh (+6.26%)
John Paulson 739,356 sh (unchged)
» More
Q1 2016

KMDA Guru Trades in Q1 2016

Jim Simons 170,300 sh (+2.41%)
John Paulson 736,117 sh (-0.44%)
» More
» Details

Insider Trades

Latest Guru Trades with KMDA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:OVAS, NAS:VCYT, NAS:CLCD, NAS:STML, NAS:IMDZ, NAS:ECYT, NAS:FBIO, OTCPK:CYDY, NAS:EIGR, NAS:CDXC, NAS:PRTO, AMEX:AST, NAS:AXSM, NAS:VBIV, OTCPK:SIGA, NAS:BDSI, NAS:OCUL, NAS:EARS, NAS:ANTH, NAS:RDHL » details
Traded in other countries:KMDA.Israel,
Kamada Ltd is an orphan drug, plasma-derived protein Therapeutics Company and develops & produces specialty plasma-derived protein therapeutics. Its product candidates include Glassia and Inhaled Alpha-1 Antitrypsin for its deficiency.

Kamada Ltd. develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company's product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises of Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other. Its business is segmented into two - Proprietary Product and Distribution. The Proprietary Product segment develops and manufactures plasma-derived therapeutics and market them in more than 15 countries. The Distribution segment distributes drugs manufactured by third-parties for critical use in Israel, produced from plasma or its derivative products.

Ratios

vs
industry
vs
history
P/B 2.04
KMDA's P/B is ranked higher than
72% of the 1075 Companies
in the Global Biotechnology industry.

( Industry Median: 3.25 vs. KMDA: 2.04 )
Ranked among companies with meaningful P/B only.
KMDA' s P/B Range Over the Past 10 Years
Min: 1.48  Med: 2.65 Max: 11.42
Current: 2.04
1.48
11.42
P/S 1.90
KMDA's P/S is ranked higher than
88% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 12.77 vs. KMDA: 1.90 )
Ranked among companies with meaningful P/S only.
KMDA' s P/S Range Over the Past 10 Years
Min: 1.6  Med: 3.14 Max: 15.22
Current: 1.9
1.6
15.22
EV-to-EBIT -14.89
KMDA's EV-to-EBIT is ranked lower than
99.99% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 20.49 vs. KMDA: -14.89 )
Ranked among companies with meaningful EV-to-EBIT only.
KMDA' s EV-to-EBIT Range Over the Past 10 Years
Min: -150.2  Med: -8.70 Max: 1528
Current: -14.89
-150.2
1528
EV-to-EBITDA -26.65
KMDA's EV-to-EBITDA is ranked lower than
99.99% of the 319 Companies
in the Global Biotechnology industry.

( Industry Median: 17.75 vs. KMDA: -26.65 )
Ranked among companies with meaningful EV-to-EBITDA only.
KMDA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -328  Med: -11.40 Max: 133
Current: -26.65
-328
133
Current Ratio 3.11
KMDA's Current Ratio is ranked lower than
63% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. KMDA: 3.11 )
Ranked among companies with meaningful Current Ratio only.
KMDA' s Current Ratio Range Over the Past 10 Years
Min: 2.21  Med: 3.19 Max: 4.42
Current: 3.11
2.21
4.42
Quick Ratio 1.95
KMDA's Quick Ratio is ranked lower than
72% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. KMDA: 1.95 )
Ranked among companies with meaningful Quick Ratio only.
KMDA' s Quick Ratio Range Over the Past 10 Years
Min: 1.45  Med: 2.32 Max: 3.59
Current: 1.95
1.45
3.59
Days Inventory 179.87
KMDA's Days Inventory is ranked lower than
66% of the 444 Companies
in the Global Biotechnology industry.

( Industry Median: 128.57 vs. KMDA: 179.87 )
Ranked among companies with meaningful Days Inventory only.
KMDA' s Days Inventory Range Over the Past 10 Years
Min: 34.72  Med: 125.92 Max: 187.18
Current: 179.87
34.72
187.18
Days Sales Outstanding 86.53
KMDA's Days Sales Outstanding is ranked lower than
67% of the 607 Companies
in the Global Biotechnology industry.

( Industry Median: 62.37 vs. KMDA: 86.53 )
Ranked among companies with meaningful Days Sales Outstanding only.
KMDA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 69.61  Med: 89.95 Max: 97.76
Current: 86.53
69.61
97.76
Days Payable 148.71
KMDA's Days Payable is ranked higher than
78% of the 444 Companies
in the Global Biotechnology industry.

( Industry Median: 57.77 vs. KMDA: 148.71 )
Ranked among companies with meaningful Days Payable only.
KMDA' s Days Payable Range Over the Past 10 Years
Min: 89.24  Med: 116.34 Max: 138.19
Current: 148.71
89.24
138.19

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 2.94
KMDA's Price/Net Current Asset Value is ranked higher than
71% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 4.83 vs. KMDA: 2.94 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
KMDA' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.31  Med: 3.84 Max: 38.53
Current: 2.94
2.31
38.53
Price/Tangible Book 2.04
KMDA's Price/Tangible Book is ranked higher than
76% of the 1012 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. KMDA: 2.04 )
Ranked among companies with meaningful Price/Tangible Book only.
KMDA' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.68  Med: 2.80 Max: 10.09
Current: 2.04
1.68
10.09
Price/Median PS Value 0.60
KMDA's Price/Median PS Value is ranked higher than
77% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. KMDA: 0.60 )
Ranked among companies with meaningful Price/Median PS Value only.
KMDA' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.57  Med: 1.15 Max: 4.84
Current: 0.6
0.57
4.84
Earnings Yield (Greenblatt) (%) -6.70
KMDA's Earnings Yield (Greenblatt) (%) is ranked higher than
57% of the 1169 Companies
in the Global Biotechnology industry.

( Industry Median: -9.30 vs. KMDA: -6.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
KMDA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 0.90 Max: 2.7
Current: -6.7
0.1
2.7

More Statistics

Revenue (TTM) (Mil) $75.77
EPS (TTM) $ -0.22
Beta1.27
Short Percentage of Float0.02%
52-Week Range $3.09 - 4.47
Shares Outstanding (Mil)36.42

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $) 332 388 420
EPS ($) -0.38 0.04 1.92
EPS w/o NRI ($) -0.38 0.04 1.92
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:KMDA

Headlines

Articles On GuruFocus.com
Weekly 3-Year Low Highlights: FMS, SNOW, KMDA, LAYN Jun 16 2014 

More From Other Websites
Kamada to Host Second Quarter Financial Results Conference Call on August 2, 2016 at 8:30 am Eastern... Jul 27 2016
ETF’s with exposure to Kamada Ltd. : July 26, 2016 Jul 26 2016
Kamada to Host Second Quarter Financial Results Conference Call on August 2, 2016 at 8:30 am Eastern... Jul 26 2016
Kamada Announces Appointment of Naveh Tov, M.D., Ph.D., to Vice President, Clinical Development and... Jun 23 2016
Shire and Kamada Announce FDA Approval of Expanded Label for Self-Infusion of Glassia for the... Jun 15 2016
Why Best Buy, Celgene, and Three Other Stocks Are Making Headlines Today Jun 15 2016
Shire and Kamada Announce FDA Approval of Expanded Label for Self-infusion of GLASSIA for the... Jun 15 2016
Kamada’s Alpha-1 Antitrypsin Now Available to Treat Graft-Versus-Host Disease on myTomorrows Early... May 25 2016
Kamada’s Alpha-1 Antitrypsin Now Available to Treat Graft-Versus-Host Disease on myTomorrows Early... May 25 2016
Kamada Ltd. :KMDA-US: Earnings Analysis: Q1, 2016 By the Numbers May 12 2016
Kamada Reports 2016 First Quarter Financial Results May 09 2016
Kamada reports 1Q loss May 09 2016
Kamada reports 1Q loss May 09 2016
Kamada Reports 2016 First Quarter Financial Results May 09 2016
Kamada to Host First Quarter Financial Results Conference Call on May 9, 2016 at 8:30 am Eastern... May 04 2016
Kamada to Host First Quarter Financial Results Conference Call on May 9, 2016 at 8:30 am Eastern... May 04 2016
Kamada Receives Two Milestone Payments under Strategic Agreements with Chiesi Farmaceutici and... May 03 2016
Kamada Receives Two Milestone Payments under Strategic Agreements with Chiesi Farmaceutici and... May 02 2016
Kamada Announces Initiation of Phase 2 Clinical Trial with Intravenous Alpha-1 Antitrypsin for the... Apr 07 2016
Kamada Announces Initiation of Phase 2 Clinical Trial with Intravenous Alpha-1 Antitrypsin for the... Apr 06 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)